T. Rowe Price Investment Management, Inc. Cytokinetics Inc Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Cytokinetics Inc stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 8,138,677 shares of CYTK stock, worth $428 Million. This represents 0.28% of its overall portfolio holdings.
Number of Shares
8,138,677
Previous 5,121,589
58.91%
Holding current value
$428 Million
Previous $359 Million
22.8%
% of portfolio
0.28%
Previous 0.22%
Shares
7 transactions
Others Institutions Holding CYTK
# of Institutions
406Shares Held
126MCall Options Held
3.29MPut Options Held
2.01M-
Black Rock Inc. New York, NY14.7MShares$772 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$602 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.51MShares$395 Million0.07% of portfolio
-
State Street Corp Boston, MA6.55MShares$345 Million0.02% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y94.58MShares$241 Million29.98% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.96B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...